Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970749 · ClinicalTrials.gov registry record
Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 55
- Enrollment target
NCT00970749: Completed study, sponsored by University of Pittsburgh.
NCT00970749 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00970749 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This is an exploratory study in which the investigators will develop a way to identify the cell responses most strongly associated with protection against chlamydia infection. This study is not driven by a hypothesis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-06 |
What the finished NCT00970749 record still lists
NCT00970749 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00970749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00970749 about?
NCT00970749 is a clinical study titled "Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis". This is an exploratory study in which the investigators will develop a way to identify the cell responses most strongly associated with protection against chlamydia infection. This study is not driven by a hypothesis.
What is the current status of trial NCT00970749?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2009-12. Estimated completion is 2010-06.
Who is sponsoring clinical trial NCT00970749?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia